Nintedanib combined with dual immunosuppression for interstitial lung disease in systemic sclerosis and rheumatoid arthritis: A systematic review and pooled multicentre real-world cohort study.
Interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) or rheumatoid arthritis (RA) carries substantial mortality, and treatment options remain limited. We investigated the effectiveness, safety, and tolerability of triple therapy combining nintedanib with two…